<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004858</url>
  </required_header>
  <id_info>
    <org_study_id>043-1819</org_study_id>
    <nct_id>NCT04004858</nct_id>
  </id_info>
  <brief_title>Prostate Margin Reduction to Reduce Acute Rectal Toxicity (PROTRACT)</brief_title>
  <acronym>PROTRACT</acronym>
  <official_title>Reducing Acute Rectal Toxicity for Hypofractionated Prostate Radiotherapy - An Multi-institution Pilot Study of Reduced PTV Margin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southlake Regional Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southlake Regional Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        1. Retrospectively validate a reduced margin schema for intermediate risk prostate
           hypofractionated VMAT treatments

        2. Demonstrate in a prospective pilot clinical trial that patients planned and treated with
           the reduced margin schema will have reduced acute rectal toxicity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypofractionated radiotherapy is being adopted as standard practice for intermediate risk
      prostate cancer patients. The objective of this project is to retrospectively validate
      whether reducing the Planning Target Volume (PTV), a margin placed around the prostate to
      account for movement and variability in patient placement, will have reduced acute rectal
      toxicity. The project will focus on patients with intermediate risk prostate cancer treated
      with hypofractionated Volumetric Modulated Arc Therapy (VMAT) from multiple institutions. The
      investigators intend to prospectively demonstrate that patients planned and treated with the
      reduced margin, along with using advanced image-guidance and consistent bladder and rectum
      preparation will have reduced acute rectal toxicity.

      The project consists of two phases: phase one is a retrospective planning study and phase two
      is a prospective pilot clinical trial.

      Phase one aims to validate the benefits of the proposed decrease in PTV margin by assessing
      whether the investigators can continue to deliver the intended radiation dose to the prostate
      while further sparing the rectum. This will be accomplished by evaluating the daily delivered
      dose on Cone-Beam Computed Tomography (CBCT), a daily scan performed during treatment that
      determines the location of the prostate and rectum. Using these CBCT scans, the investigators
      can reconstruct the radiation dose delivered to any organs of interest which was affected by
      their relative positions each day. There are two parts in this phase one retrospective
      planning study. Part one will focus on 30 intermediate risk prostate cancer cases already
      treated with hypofractionation (60 Gy in 20 fractions) using the standard PTV margins from
      all three participating institutions. All 30 cases will then be re-planned using the reduced
      PTV margin and dose reconstruction will be performed on daily CBCT to confirm adequate target
      coverage of the prostate. Part two aims to demonstrate that the reduced PTV margin can help
      enable hypofractionation. Thirty cases that were originally intended to receive a
      hypofractionated regimen of 60 Gy in 20 fractions but had to either switch to a standard
      fractionation treatment of 78 Gy in 39 fractions (a regimen used when 60Gy in 20 fractions is
      not achievable), or where there had to be compromised target coverage of the prostate, due to
      Organs at Risk (OAR) receiving unacceptable doses of radiation, will be selected. These cases
      will be re-planned with the validated smaller PTV margin to illustrate that they would now be
      eligible to receive hypofractionation due to the reduced dose to OARs.

      Phase two aims to demonstrate that patients treated with the reduced PTV margin will have
      reduced acute rectal toxicity as evaluated by the Cancer Care Ontario (CCO) Expanded Prostate
      Cancer Index Composite for Clinical Practice (EPIC-CP) Quality of Life (QOL) questionnaire.
      Two groups of patients will be accrued: one group of 25 patients will be planned and treated
      with the current standard PTV margin as the control group, while the second group of 25
      patients will be planned and treated with the reduced PTV margin validated from the phase one
      retrospective study. A comparison of rectal toxicity scores between these two groups will
      then be carried out using the EPIC-CP questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The prospective pilot study will consist of two cohorts of patients: one cohort planned with the current standard PTV margin and the second cohort planned with the reduced margin validated from the retrospective study. The first cohort will be recruited while the retrospective study is being carried out and the second cohort will be accrued once the retrospective validation is completed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced acute rectal toxicity from reduced PTV margin</measure>
    <time_frame>6 months</time_frame>
    <description>Patients planned and treated with reduced PTV margin will have a change of 2 points in Cancer Care Ontario (CCO) Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) bowel symptom scores, demonstrating better toxicity outcomes. This patient reported outcome questionnaire evaluates bowel symptom scores in four aspects: rectal pain or urgency of bowel movement, increased frequency of bowel movements, overall problems with bowel movements, and bloody stools. Each aspect has a score ranging from 0 to 4. The total scores for an individual patient ranges from 0 to 16, with lower score indicating a better outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard margin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient cohort planned with the current standard PTV margin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced margin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient cohort planned with the reduced margin validated from the retrospective study</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation therapy</intervention_name>
    <description>Patient will receive 60Gy in 20 fractions as per standard practice</description>
    <arm_group_label>Reduced margin</arm_group_label>
    <arm_group_label>Standard margin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male patients with intermediate-risk prostate cancer receiving external beam
             radiotherapy

          2. Age greater than or equal to 18 years

          3. Agreeable to proposed follow-up schedule and able to complete quality of life
             questionnaire as proposed

        Exclusion Criteria:

          1. Previous radiotherapy to the pelvic region

          2. Inflammatory bowel disease or chronic colitis.

          3. Connective tissue disorders such as scleroderma.

          4. Patients with hip replacements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patient diagnosed with intermediate-risk prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beibei Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Cho, MD</last_name>
    <phone>905-895-4521</phone>
    <phone_ext>6539</phone_ext>
    <email>ccho@southlakeregional.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beibei Zhang, PhD</last_name>
    <phone>905-895-4521</phone>
    <phone_ext>6083</phone_ext>
    <email>bzhang@southlakeregional.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>National Comprehensive Cancer Network: Prostate cancer, 2016. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</citation>
  </reference>
  <reference>
    <citation>Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, Witte MG, Heemsbergen WD. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):680-9. doi: 10.1016/j.ijrobp.2016.01.031. Epub 2016 Jan 22.</citation>
    <PMID>27055398</PMID>
  </reference>
  <reference>
    <citation>Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999 Jan 23;353(9149):267-72.</citation>
    <PMID>9929018</PMID>
  </reference>
  <reference>
    <citation>Alayed Y et al: Clinical impact of reducing planning target volume margins during radiation therapy for localized prostate cancer: early outcomes of a 2-stage prospective trial. Int J Radiat Oncol Biol Phys 93:(S)E249, 2015</citation>
  </reference>
  <reference>
    <citation>Nijkamp J, Pos FJ, Nuver TT, de Jong R, Remeijer P, Sonke JJ, Lebesque JV. Adaptive radiotherapy for prostate cancer using kilovoltage cone-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):75-82. Epub 2007 Sep 17.</citation>
    <PMID>17869445</PMID>
  </reference>
  <reference>
    <citation>Gill SK, Reddy K, Campbell N, Chen C, Pearson D. Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins. J Appl Clin Med Phys. 2015 Nov 8;16(6):252â€“262. doi: 10.1120/jacmp.v16i6.5691.</citation>
    <PMID>26699581</PMID>
  </reference>
  <reference>
    <citation>Battista JJ, Johnson C, Turnbull D, Kempe J, Bzdusek K, Van Dyk J, Bauman G. Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):874-80. doi: 10.1016/j.ijrobp.2013.07.006. Epub 2013 Aug 24.</citation>
    <PMID>23978708</PMID>
  </reference>
  <reference>
    <citation>Nuver TT, Hoogeman MS, Remeijer P, van Herk M, Lebesque JV. An adaptive off-line procedure for radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1559-67. Epub 2007 Feb 15.</citation>
    <PMID>17306934</PMID>
  </reference>
  <reference>
    <citation>Engels B, Soete G, Gevaert T, Storme G, Michielsen D, De Ridder M. Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer. Radiother Oncol. 2014 Apr;111(1):106-9. doi: 10.1016/j.radonc.2014.02.009. Epub 2014 Mar 13.</citation>
    <PMID>24631146</PMID>
  </reference>
  <reference>
    <citation>Quon HC et al: PATRIOT trial: randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time. J Clin Oncol 33:(S)6-6, 2015.</citation>
  </reference>
  <reference>
    <citation>Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.</citation>
    <PMID>28296582</PMID>
  </reference>
  <reference>
    <citation>Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.</citation>
    <PMID>27339115</PMID>
  </reference>
  <reference>
    <citation>Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep;186(3):865-72. doi: 10.1016/j.juro.2011.04.085. Epub 2011 Jul 23.</citation>
    <PMID>21788038</PMID>
  </reference>
  <reference>
    <citation>Howell D et al: Feasibility of implementing EPIC-CP: recommendations to enhance the quality of person-centred clinical care of men with early-stage prostate cancer. Cancer Care Ontario report.</citation>
  </reference>
  <reference>
    <citation>Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905.</citation>
    <PMID>11113727</PMID>
  </reference>
  <reference>
    <citation>Korzeniowski M, Kalyvas M, Mahmud A, Shenfield C, Tong C, Zaza K, Howell D, Brundage M. Piloting prostate cancer patient-reported outcomesin clinical practice. Support Care Cancer. 2016 May;24(5):1983-1990. doi: 10.1007/s00520-015-2949-5. Epub 2015 Oct 24.</citation>
    <PMID>26498748</PMID>
  </reference>
  <reference>
    <citation>Lee WR et al: RTOG 0415: A phase III randomized study of hypofractionated 3DCRT/IMRT versus conventionally fractionated 3DCRT/IMRT in patients treated for favorable-risk prostate cancer.</citation>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southlake Regional Health Centre</investigator_affiliation>
    <investigator_full_name>Beibei Zhang</investigator_full_name>
    <investigator_title>Medical Physicist</investigator_title>
  </responsible_party>
  <keyword>Radiation toxicity</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Margin reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

